FYI: Your GLP-1 fears, answered.

Okay.

We've gotten a lot of questions about GLP-1 dangers this week, so today we open the mailbag. Some of the fears are real, some are TikTok, and some are in between, so we're going to go through 8 of them with actual data.

If you've ever sent your mom a link to prove something she sent you is wrong, this issue is for you.

This is Off Label, Not Medical Advice.

Let's go.

The Morning Read: GLP-1 fear is half real, half TikTok. Here's how to tell which is which.

Three things you should know happened recently, because the rest of this issue hangs on them.

One. On March 5, 2026, the FDA issued a warning letter (MARCS-CMS 717576) to Novo Nordisk, citing failure to timely report three deaths including one suicide, one suicidal ideation case, and one disabling stroke. The inspection that triggered this was in January and February of 2025, over a year before the letter went out.

Two. At the October 2025 American Academy of Ophthalmology annual meeting, researchers from the University of Ottawa, University of Toronto, McMaster, and UCLA presented a study of 117,173 patients in the WHO global drug safety database. Semaglutide users had a 68.6x higher reporting rate for non-arteritic anterior ischemic optic neuropathy (NAION, a rare vision loss condition) versus comparator drugs. Important: tirzepatide (Mounjaro/Zepbound) showed no significant association in the same study.

Three. Lawsuits against Novo Nordisk and Eli Lilly are climbing. There are two federal multidistrict litigations (MDLs) currently underway.

Those are the facts. Now, the questions.

Eight questions. Real fears. Actual data.

Serious for the company. Probably not a reason for you to stop your drug.

The warning letter is about reporting timeliness, not a conclusion that the drugs caused specific deaths. The FDA explicitly noted it did not conclude causation. What the FDA found was procedural: Novo Nordisk's internal system rejected certain adverse event reports (for example, a disabling stroke case was dismissed because the patient said the stroke wasn't drug-related), and in one case a suicidal ideation report sat in "medical review" status for nearly two months before being submitted.

That's a corporate governance problem. Whether it resulted in patient harm is a separate question the MDL trials will eventually address. For most individual patients, this is not a reason to stop. It is a reason to have an informed conversation with your prescriber about your specific risk factors.

Real. Rare. Semaglutide-specific.

The 68.6x figure is a reporting rate in the WHO drug safety database, not an absolute incidence rate. Absolute incidence data from a recent VA study pegged NAION at roughly 123 per 100,000 person-years on semaglutide, compared to 67 per 100,000 on SGLT2 inhibitors. That's still low in absolute terms.

Higher-risk groups: people with diabetic retinopathy, hypertension, sleep apnea, age 50+. Men appear to be at about 3x the risk of women for this specific complication.

Important distinction: this risk applies to semaglutide (Ozempic, Wegovy, Rybelsus). The same study found tirzepatide (Mounjaro, Zepbound) showed no significant association with NAION. If you're on a tirzepatide product, the most alarming GLP-1 vision study does not implicate your drug.

Do this: get a baseline eye exam before starting a GLP-1. Report any sudden vision changes immediately. If you have diabetic retinopathy already, this is a conversation with your ophthalmologist, not just your prescriber.

The range matters. So does what you do about it.

The authoritative 2024 review from Diabetes, Obesity and Metabolism (Neeland et al.) puts lean mass loss at 15 to 40% of total weight lost on GLP-1 therapies. The STEP-1 trial of semaglutide came in at 45.2%. SURMOUNT-1 of tirzepatide (highest dose) came in at 25.7%.

The variation across that range is largely driven by whether patients are doing resistance training and eating enough protein. Patients doing neither land near the upper end. Patients with structured protein and lifting land near the lower end or below.

The target, according to multiple clinical sources: 0.8 to 1.2 grams of protein per pound of lean body mass daily and resistance training 2 to 3 times per week. Not optional if you want to keep the weight off long-term. Muscle tissue drives your resting metabolic rate, so the muscle you don't preserve now is weight you regain later when you stop the drug.

Most patients get told "diet and exercise." What you actually need is "protein and lift heavy." There's a difference.

Most people regain a significant portion. NPR ran a piece on this in April 2026.

Fat comes back faster than muscle does. If you lost 50 pounds on the drug (say 35 pounds of fat and 15 pounds of muscle), when you stop, the fat returns quickly while the muscle rebuild takes deliberate work. Net: you end up with a worse body composition than when you started, even if the number on the scale is similar.

The answer isn't "never stop." It's "have a plan." Structured protein, resistance training, gradual dose reduction with your doctor guiding the taper instead of cold-turkey. Some patients cycle off successfully. Many don't. Knowing which group you're in before you stop matters.

We know more than people think. Less than they assume.

Semaglutide was FDA-approved in 2017 for Ozempic and 2021 for Wegovy. That's 8 years of real-world data on the diabetes use and about 4 to 5 years on weight-loss use. Longer than many people assume. Shorter than something like metformin (60+ years of data) or statins (30+ years).

Most expected risks have likely surfaced by now. Gastroparesis surfaced. NAION surfaced. Muscle loss surfaced. Thyroid tumor risk in rodents never materialized in humans after a decade of exposure. Decade-plus effects remain somewhat unknown, but "we don't know anything" overstates the gap.

The honest framing: enough data to make informed decisions, not enough data to make guarantees. That's true for most medications in the first decade of use.

Real but cosmetic. Not a medical side effect.

"Ozempic face" describes the bonier, looser-skinned look that comes from rapid facial fat loss. It happens with any rapid weight loss, including bariatric surgery. It's a consequence of losing fat faster than skin can adapt, not a unique drug effect.

What reduces it: slower weight loss (0.5 to 1% of body weight per week is ideal, not 2%+), staying well-hydrated, and preserving muscle under the skin through resistance training. Some patients eventually pursue cosmetic treatments. Most adjust over time as skin remodels.

Separating this from real medical risks (NAION, gastroparesis, muscle loss) matters. If you're worrying about your face while not worrying about protein intake, you're worrying about the wrong thing.

Allegedly. Not confirmed in the medical literature.

Gastroparesis (stomach paralysis) is a real, rare GLP-1 complication. Most patients see symptom improvement within 4 to 5 weeks of stopping the drug, which matches semaglutide's clearance half-life. Some patients report persistent symptoms for months.

The "permanent" framing is real in lawsuits and plaintiff stories. It is not yet confirmed in peer-reviewed medical literature. A 2023 Diabetes Therapy review noted that mild to moderate gastric delay typically reverses after stopping. Persistent cases exist but causal permanence has not been clinically established.

If you had GI motility issues before starting a GLP-1, you probably should not be on one. If you develop persistent gastroparesis while on one, that's a stop-the-drug-and-see-a-gastroenterologist situation, not a wait-it-out situation.

If you have the specific family history, yes. If not, probably not.

The boxed warning on Ozempic and Wegovy comes from rat studies where semaglutide caused medullary thyroid C-cell tumors. After 10+ years of real-world semaglutide use across tens of millions of patients globally, no reliable human data has confirmed increased thyroid cancer risk. A recent review noted that GLP-1s "do not appear to increase the risk of thyroid cancer in humans."

Absolute contraindication: if you have personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia type 2 (MEN2) syndrome, GLP-1s are not for you. Period.

Everyone else: this fear is disproportionate to the actual risk. You're better off worrying about NAION, gastroparesis, and muscle loss, which have actual human data behind them.

Three things to internalize from all eight questions.

3,619 lawsuits against an 11 million user base is a 0.033% litigation rate. NAION incidence is roughly 123 per 100,000 person-years on semaglutide. That's still rare. Both things can be true: real harm happens AND it's not the statistical norm. Resist the TikTok framing that says either everything is fine or everyone is dying.

The most alarming recent vision loss study was semaglutide-specific. Tirzepatide showed no significant NAION association. The dose-response relationship for Wegovy vs Ozempic suggests higher doses and faster weight loss increase risk. This matters for switchers and for prescribing conversations.

The dramatic stories dominate TikTok: stomach paralysis, blindness, suicide ideation. The more common challenges are quieter: losing 15-40% of your weight as muscle, then regaining fat faster than muscle when you stop. These are preventable with protein and lifting, but only if someone tells you.

Text your doctor this: "I've been reading about the FDA warning letter to Novo Nordisk and the recent studies on NAION vision loss. Given my specific risk factors, can we review my family history of thyroid cancer, any eye conditions, GI issues, and whether a slower dose titration might reduce some of these risks? I'd also like to talk about a protein and strength training plan to minimize muscle loss."

Copy, paste, send. That's the single most informed conversation you can have with your prescriber right now.

Law firm advertising is shaping how people feel about their medication. TV spots, Google ads, Facebook sponsored posts, TikTok creators paid to tell fear stories. All running against an 11 million user base. The information environment is distorted by economic incentives on both sides (pharma wants to downplay, plaintiff lawyers want to amplify, honest truth sits in the middle).

The TikTok algorithm rewards the scariest experiences. If you've watched one "Ozempic made me sick" video, the next ten in your feed will be the same. This is not Ozempic being uniquely dangerous. This is TikTok being TikTok.

HR departments are fielding GLP-1 safety questions at open enrollment. Benefits teams now have FAQs about Wegovy, Zepbound, and Foundayo. This is a new HR competency that didn't exist two years ago.

"Ozempic face" has entered plastic surgery marketing. High-end surgeons in NYC, LA, and Miami now advertise "Ozempic face correction" packages. The cosmetic fear has reached commercial saturation.

Peter Attia's podcast and Sermo's physician network have been more balanced than mainstream media. If you want nuanced GLP-1 safety content, these are worth following. Mainstream coverage tends to either breathless-positive (wellness media) or breathless-negative (tabloid/legal-adjacent).

Watch this: the June 2, 2026 Science Day hearing in the GLP-1 MDL. Judge Karen Marston will hear both sides present the underlying science before the bellwether trials begin. If the plaintiffs' scientific case holds up under scrutiny, the first 3 to 5 verdicts (expected late 2026 or 2027) will trigger a settlement wave. If the science doesn't hold, the litigation thins out. Either way, this is one of the most important upcoming legal events in GLP-1 history. For Novo Nordisk (NVO) and Eli Lilly (LLY) shareholders, Science Day outcomes will move stock prices.

Tomorrow: we're back to news day. A story that just broke, what it means for anyone planning to start, switch, or stop a GLP-1 in the next six months. The headline version doesn't tell you what actually matters.

Hit reply and tell us what you want us to cover. Every reply is read. Story tips: [email protected]

See you in your inbox.

— Off Label

This is Off Label, Not Medical Advice. Content is for informational purposes only. Always consult a qualified healthcare provider before making medical decisions. This applies especially to any decision to start, stop, switch, or change dosing of a GLP-1 medication based on safety concerns.